What is the address of V-Bio Fund 2?

The registered office of V-Bio Fund 2 is located at Pieter van Reysschootlaan 2 box 104, 9051 Gent.

Is V-Bio Fund 2 still active?

Yes. According to the CBE (29 October 2026) V-Bio Fund 2 is active, legal situation “Normale toestand”, started on 11 December 2020.

Is V-Bio Fund 2 registered on Peppol?

Yes, V-Bio Fund 2 is registered on the Peppol network with ID 0208:0759685291.

What is the enterprise number of V-Bio Fund 2?

The enterprise number of V-Bio Fund 2 is BE0759685291.

When was V-Bio Fund 2 founded?

V-Bio Fund 2 was founded on 11 December 2020.

Who owns V-Bio Fund 2?

It owns 75% of Jay Therapeutics NV, 39.6% of Trim Therapeutics NV, 19.8% of Tanai Therapeutics NV, 14.3% of AstriVax Therapeutics NV, 13.6% of Flindr Therapeutics BV and 11.9% of Protealis NV itself.

Is V-Bio Fund 2 a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 December 2020; 5 annual accounts filed, latest fiscal year 2025.

How much profit did V-Bio Fund 2 make in 2025?

V-Bio Fund 2 recorded a loss after taxes of € 2,217,928 in financial year 2025.

What is the revenue of V-Bio Fund 2?

As a small company, V-Bio Fund 2 is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -2,144,878.

V-Bio Fund 2 (Public Limited) - Gent - BE0759685291

Dossier V-Bio Fund 2, printed on 29 October 2026 from databakkes.be/en/0759685291/v-bio-fund-2. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Busy address KBO

13 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

V-Bio Fund 2 from Gent, company number BE0759685291, closed financial year 2025 with a result of € -2.2 million after tax. For that financial year V-Bio Fund 2 recorded a gross margin of € -2.1 million and equity of € 51.8 million. Compared with financial year 2024, the result moved from € -2.2 million to € -2.2 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.

What it is worth Growing

€ 51.8 million

▲ 87% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -2.2 million

▼ 3 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2.7 million

▲ € 2.5 million vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -12.7 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -2,502,308 Gross margin 2022: € -2,502,308 First fiscal year in the series	€ -2,129,600 Gross margin 2023: € -2,129,600 ▲ € 372,708 vs 2022 (€ -2,502,308) Favourable step	€ -2,129,600 Gross margin 2024: € -2,129,600 Unchanged (€ -2,129,600) Unchanged	€ -2,144,878 Gross margin 2025: € -2,144,878 ▼ € 15,278 vs 2024 (€ -2,129,600) Unfavourable step	▼ € 15,278
Profit after taxes	€ -2,535,416 Profit after taxes 2022: € -2,535,416 First fiscal year in the series	€ -3,916,212 Profit after taxes 2023: € -3,916,212 ▼ € 1.4 million vs 2022 (€ -2,535,416) Unfavourable step	€ -2,155,453 Profit after taxes 2024: € -2,155,453 ▲ € 1.8 million vs 2023 (€ -3,916,212) Favourable step	€ -2,217,928 Profit after taxes 2025: € -2,217,928 ▼ € 62,475 vs 2024 (€ -2,155,453) Unfavourable step	▼ € 62,475
Equity	€ 13,068,090 Equity 2022: € 13,068,090 First fiscal year in the series	€ 19,220,536 Equity 2023: € 19,220,536 ▲ 47% vs 2022 (€ 13,068,090) Favourable step	€ 27,681,144 Equity 2024: € 27,681,144 ▲ 44% vs 2023 (€ 19,220,536) Favourable step	€ 51,781,968 Equity 2025: € 51,781,968 ▲ 87% vs 2024 (€ 27,681,144) Favourable step	▲ 87%
Total debts	€ 0 Total debts 2022: € 0 First fiscal year in the series	€ 0 Total debts 2023: € 0 Unchanged (€ 0) Unchanged	€ 532,400 Total debts 2024: € 532,400 Unchanged (€ 0) Unfavourable step	€ 0 Total debts 2025: € 0 ▼ 100% vs 2024 (€ 532,400) Favourable step	▼ 100%
Cash	€ 1,351,960 Cash 2022: € 1,351,960 First fiscal year in the series	€ 2,308,712 Cash 2023: € 2,308,712 ▲ 71% vs 2022 (€ 1,351,960) Favourable step	€ 147,042 Cash 2024: € 147,042 ▼ 94% vs 2023 (€ 2,308,712) Unfavourable step	€ 2,684,617 Cash 2025: € 2,684,617 ▲ € 2.5 million vs 2024 (€ 147,042) Favourable step	▲ € 2.5 million
Retained profit	€ -4,429,899 Retained profit 2022: € -4,429,899 First fiscal year in the series	€ -8,346,111 Retained profit 2023: € -8,346,111 ▼ € 3.9 million vs 2022 (€ -4,429,899) Unfavourable step	€ -10,501,564 Retained profit 2024: € -10,501,564 ▼ € 2.2 million vs 2023 (€ -8,346,111) Unfavourable step	€ -12,719,492 Retained profit 2025: € -12,719,492 ▼ € 2.2 million vs 2024 (€ -10,501,564) Unfavourable step	▼ € 2.2 million
Balance sheet total	€ 13,068,090 Balance sheet total 2022: € 13,068,090 First fiscal year in the series	€ 19,220,536 Balance sheet total 2023: € 19,220,536 ▲ 47% vs 2022 (€ 13,068,090) Unchanged	€ 28,213,544 Balance sheet total 2024: € 28,213,544 ▲ 47% vs 2023 (€ 19,220,536) Unchanged	€ 51,781,968 Balance sheet total 2025: € 51,781,968 ▲ 84% vs 2024 (€ 28,213,544) Unchanged	▲ 84%

Key figures of V-Bio Fund 2, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to V-Bio Fund 2?

What happened at V-Bio Fund 2 in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 18, 2026 New annual accounts for financial year 2025: loss of € 2.2 million. Source: NBB ↗
Dec 11, 2020 New establishment in Gent. KBO
Dec 11, 2020 Start of the company according to the CBE. KBO

In short

From € 2.5 million loss in 2022 to € 2.2 million loss in 2025.

Original PDFs at the National Bank ↗

Establishments

Establishment units

Physical locations of this company

Registered office

Pieter van Reysschootlaan 2 box 104

9051 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.

All companies at this address →

CD-Vastgoed

€ 437,585 gross margin · 2025

V-BIO PARTNERS 1

€ -2,244 gross margin · 2025

V-BIO MANAGEMENT 1

€ 822,886 revenue · 2025

V-Bio Fund 1

€ -903,749 gross margin · 2025

V-Bio Co-Invest 1-1

€ -16,692 gross margin · 2025

+8 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0759.685.291
VAT number: BE 0759.685.291
Registered office: Pieter van Reysschootlaan 2 bus 104, 9051 Gent
Names & denominations: V-Bio Fund 2
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 11 December 2020
Peppol: Active · Active since 19 Nov 2025
Contact: v-bio.ventures [email protected]

View on CBE Public ↗ Annual accounts (NBB) ↗

V-Bio Fund 2